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Purpose: In this analysis, we compared costs and
explored the cost-effectiveness of subsequent-line treat-
ment with cetuximab or panitumumab in patients with
wild-type KRAS (exon 2) metastatic colorectal cancer
(mCRC) after previous chemotherapy treatment failure.
Data were used from ASPECCT (A Study of Panitu-
mumab Efﬁcacy and Safety Compared to Cetuximab in
Patients With KRAS Wild-Type Metastatic Colorectal
Cancer), a Phase III, head-to-head randomized non-
inferiority study comparing the efﬁcacy and safety of
panitumumab and cetuximab in this population.
Methods: A decision-analytic model was developed to
perform a cost-minimization analysis and a semi-Markov
model was created to evaluate the cost-effectiveness of
panitumumab monotherapy versus cetuximab monother-
apy in chemotherapy-resistant wild-type KRAS (exon 2)
mCRC. The cost-minimization model assumed equivalent
efﬁcacy (progression-free survival) based on data from
ASPECCT. The cost-effectiveness analysis was conducted
with the full information (uncertainty) from ASPECCT.
Both analyses were conducted from a US third-party
payer perspective and calculated average anti–epidermal
growth factor receptor doses from ASPECCT. CostsAccepted for publication March 14, 2016.
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1376associated with drug acquisition, treatment administra-
tion (every 2 weeks for panitumumab, weekly for
cetuximab), and incidence of infusion reactions were
estimated in both models. The cost-effectiveness model
also included physician visits, disease progression mon-
itoring, best supportive care, and end-of-life costs and
utility weights estimated from EuroQol 5-Dimension
questionnaire responses from ASPECCT.
Findings: The cost-minimization model results dem-
onstrated lower projected costs for patients who received
panitumumab versus cetuximab, with a projected cost
savings of $9468 (16.5%) per panitumumab-treated
patient. In the cost-effectiveness model, the incremental
cost per quality-adjusted life-year gained revealed pan-
itumumab to be less costly, with marginally better
outcomes than cetuximab.
Implications: These economic analyses comparing
panitumumab and cetuximab in chemorefractory
wild-type KRAS (exon 2) mCRC suggest beneﬁts in
favor of panitumumab. ClinicalTrials.gov identiﬁer:
NCT01001377. (Clin Ther. 2016;38:1376–1391)
& 2016 The Authors. Published by Elsevier HS
Journals, Inc.
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Colorectal cancer (CRC) is the third most common
cancer in both men and women in the United StatesVolume 38 Number 6
C.N. Graham et al.and the second leading cause of cancer death.1 In
2015, it was estimated that there would be 132,700
new cases of colon and rectum cancer and an
estimated 49,700 people would die of this disease.
Approximately 20% have metastatic CRC (mCRC) at
diagnosis, and metastases eventually develop in 50%
to 60% of all patients.1–3 Patients with mCRC
experience signiﬁcant morbidity and diminished qual-
ity of life. The 5-year relative survival rate iso13% in
patients with mCRC, indicating a continued need to
improve treatment outcomes.1 Surgical resection of
metastases is curative in a very small proportion of
patients; therefore, the goal of treatment for most
patients with mCRC is to prolong survival while
maintaining quality of life.
Chemotherapy is the ﬁrst treatment option for
metastatic disease when tumor lesions are not fully
resectable. Regimens consisting of ﬂuoropyrimidine
and oxaliplatin (ie, FOLFOX) or irinotecan (ie,
FOLFIRI) can be considered standard options for
ﬁrst-line treatment of mCRC. In randomized trials in
which patients received either FOLFIRI followed by
FOLFOX or FOLFOX followed by FOLFIRI, median
progression-free survival (PFS) ranged from 7 months
to 8.5 months.4,5 In addition to various chemother-
apeutic regimens, current treatments for mCRC in-
clude targeted monoclonal antibodies directed against
the epidermal growth factor receptor (EGFR), such as
panitumumab and cetuximab, and bevacizumab, a
humanized monoclonal antibody that binds the vas-
cular endothelial growth factor. Trials comparing the
use of these types of targeted therapies in patients with
mCRC have demonstrated a signiﬁcant increase in
survival.6–12
Patients with RAS gene mutations should not be
treated with an anti-EGFR agent because these muta-
tions are predictive of a lack of response to panitu-
mumab and cetuximab.2,3 Approximately 50% of
patients with mCRC have tumors exhibiting RAS
mutations,13 including 40% with KRAS (exon 2)
mutations.14 Therefore, 50% to 60% of patients
with mCRC would be eligible for treatment with
panitumumab and cetuximab. Identifying KRAS
status and ultimately RAS status through genotyping
may reduce treatment costs by allowing physicians
to target patients who are likely to beneﬁt from
treatment with EGFR inhibitors and to minimize the
number of patients receiving anti-EGFR agents who
are unlikely to respond favorably.June 2016Several clinical trials have been conducted to
study targeted therapies in the treatment of mCRC.
The ASPECCT (A Study of Panitumumab Efﬁcacy
and Safety Compared to Cetuximab in Patients With
KRAS Wild-Type Metastatic Colorectal Cancer)
clinical trial was designed to evaluate the efﬁcacy
and safety of treatment with panitumumab
(n ¼ 499) versus cetuximab (n ¼ 500) in patients
with previously treated, chemotherapy-resistant,
wild-type KRAS (exon 2) mCRC. This therapy
resulted in an estimated median PFS of 4.1 months
(95% CI, 3.2–4.8) in the panitumumab arm and 4.4
months (95% CI, 3.2–4.8) in the cetuximab arm.
The estimated median overall survival (OS) was 10.4
months (95% CI, 9.4–11.6) in the panitumumab
arm and 10.0 months (95% CI, 9.3–11.0) in the
cetuximab arm.15 These results indicate noninferior
OS in patients with wild-type KRAS (exon 2) mCRC
(panitumumab vs cetuximab hazard ratio [HR], 0.97
[95% CI, 0.84–1.11]). Although the difference in OS
between treatments is not statistically signiﬁcant, it
does highlight a trend in OS slightly favoring
panitumumab.
Economic modeling can be used to help decision-
makers determine the relative monetary value of 1
treatment versus another given the health care cost
challenges and constraints that payers face. Cost-
minimization analysis is a method that should be used
only to measure and compare the costs of different
medical interventions in economic evaluations of trials
demonstrating no statistically signiﬁcant difference in
efﬁcacy. However, Briggs and O’Brien16 suggest that
even noninferior efﬁcacy results, such as those
reported in the ASPECCT study, can beneﬁt from
probabilistic cost-effectiveness modeling, as the un-
certainty around the point estimates are considered in
the Monte-Carlo sampling.
Recently, the American Society of Clinical Oncol-
ogy announced an initiative focusing on value in
cancer care.17 The value framework will consider a
particular treatment regimen’s effectiveness, the
severity of the expected side effects, and the
treatment’s costs to evaluate the relative value of
the treatments that are available and to determine
the best treatment approach. To this point, economic
modeling of noninferior trial results can assist with
estimation of treatment costs (drug acquisition and
administration) as well as the costs of side effects or
toxicities between 2 treatments.1377
Clinical TherapeuticsPublished cost-effectiveness studies evaluating
subsequent-line treatment with cetuximab or panitu-
mumab in patients with wild-type KRAS (exon 2)
mCRC have only examined the cost-effectiveness of
these anti-EGFR therapies relative to best supportive
care (BSC).18–20 To our knowledge, an economic
model that directly compares panitumumab versus
cetuximab in the treatment of patients with mCRC
after prior chemotherapy treatment failure has not yet
been published.
Given the noninferior efﬁcacy results demon-
strated in the ASPECCT study, we developed a
decision-analytic model to perform a cost-
minimization analysis, assuming equivalent efﬁcacy
(PFS), between panitumumab (intravenous infusion,
6 mg/kg every 2 weeks until disease progression) and
cetuximab (intravenous infusion, loading dose of
400 mg/m2 and weekly maintenance doses of 250
mg/m2 until disease progression) monotherapy in
chemorefractory patients with wild-type KRAS
(exon 2) mCRC. Data from the head-to-head AS-
PECCT trial were used.
To examine the beneﬁt suggested by Briggs and
O’Brien16 of probabilistic cost-effectiveness modeling
using noninferiority trial results, we also developed a
semi-Markov model to evaluate the cost-effectiveness
of panitumumab monotherapy versus cetuximab
monotherapy in chemotherapy-resistant patients with
wild-type KRAS (exon 2) mCRC using the full
information (uncertainty) from the ASPECCT trial.
Both analyses were conducted from a US third-party
payer perspective.MATERIALS AND METHODS
Population
The model population in both models was based on
the patient population included in the head-to-head
ASPECCT clinical trial comparing panitumumab and
cetuximab in the treatment of mCRC. Brieﬂy, this
population was deﬁned as adults (ageZ18 years) with
wild-type KRAS (exon 2) with a diagnosis of mCRC
for whom previous treatment with regimens contain-
ing irinotecan and oxaliplatin had failed and for
whom at least 1 thymidylate synthase inhibitor had
been received. In addition, enrolled patients had an
Eastern Cooperative Oncology Group status of 0, 1,
or 2 and adequate hematologic, renal, hepatic, and
metabolic function.1378Model Structure
The cost-minimization analysis assumed panitumu-
mab and cetuximab had equivalent PFS and estimated
the costs associated with drug acquisition, treatment
administration frequency (biweekly for panitumumab,
weekly for cetuximab), and incidence of infusion
reactions. Costs were estimated over the time horizon
of the model, which was determined according to the
length of therapy as reﬂected by the average PFS. The
cost-minimization model structure is illustrated in
Figure 1.
The cost-effectiveness analysis took the form of a
probabilistic semi-Markov model, allowing patients to
transition to various health states over time (Figure 2).
In the cost-effectiveness analysis, the model begins
with a cohort of patients initiating subsequent mCRC
treatment after discontinuing failed chemotherapy
after progression. Patients cycle through the model
every 2 weeks. During each cycle, patients may
transition to different mutually exclusive health states
or stay in the same health state based on health state
transition probabilities; each health state has a corre-
sponding cost and outcome. For the base-case time
horizon, Markov cycles are repeated for the lifetime of
a patient. The semi-Markov model concludes when
the entire patient cohort has died. Total costs and
outcomes are calculated by summing across cycles.
Inputs
Transition Probabilities
In clinical trials of oncology products, Kaplan-
Meier plots for PFS and OS are often right-censored
because data collection ends before all patients expe-
rience disease progression and/or death. Because of
the right censoring of the curves, parametric survival
curves can be ﬁt to patient-level survival data to
extrapolate beyond the data collection period.
In the cost-minimization analysis, data from the
ASPECCT clinical trial were used to conduct para-
metric survival analyses on the PFS of wild-type KRAS
(exon 2) patients treated with panitumumab. The
parametric survival modeling was coded in SAS
version 9.3 (SAS Institute, Inc, Cary, North Carolina)
by using the LIFEREG procedure. Three parametric
models were tested, based on the intrinsic assumptions
they make regarding changes to the hazard rate over
time. The models were exponential, Weibull, and log-
logistic. Based on graphical overlay of the curves and
the Kaplan-Meier plot, goodness-of-ﬁt statisticsVolume 38 Number 6
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Figure 1. Cost-minimization model structure.
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long-term survival projections (as suggested by
Latimer21), the best-ﬁt survival curve for panitumu-
mab was the Weibull, which was selected as the base-
case estimate of mean PFS for panitumumab as well as
cetuximab given that the model assumed both treat-
ments had the same efﬁcacy.
In the cost-effectiveness analysis, transition proba-
bilities to disease progression and death for panitu-
mumab and cetuximab were based on parametricEnter
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of PFS and OS from the ASPECCT clinical trial. In
contrast to the cost-minimization analysis, separate
parametric survival curves were estimated for panitu-
mumab and cetuximab by including a covariate for
panitumumab treatment in the regression equations;
this approach accounted for noninferior ASPECCT
trial results (OS HR, 0.97) and the difference in
efﬁcacy between panitumumab and cetuximab. Using
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Clinical TherapeuticsWeibull was selected as the best-ﬁt curve for panitu-
mumab and cetuximab for both PFS and OS in the
cost-effectiveness model (Figures 3 and 4).Costs
Aside from the efﬁcacy input parameters, sources
were consistent for the input parameters used in both
models. Drug acquisition costs in the base-case anal-
ysis were modeled by using Medicare average sales
prices from the payment allowance limits for Medi-
care Part B drugs.22 Wholesale acquisition costs from
Red Book23 were examined in scenario analyses.
Product exposure, deﬁned as the average dose
delivered, percentage of doses administered, and
therapy duration (for subsequent therapy), were
calculated from data in the ASPECCT clinical trial
for direct treatment comparators. Premedication, drug
acquisition and administration costs, dosing, duration,
and other regimen-speciﬁc inputs are presented in
Table I, along with sources and assumptions.
Adverse event treatment incidence and cost inputs
are presented in Table II, and non–regimen-speciﬁcPanitumumab K
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Figure 3. Progression-free survival Kaplan-Meier and fitte
of-fit of progression-free survival curves: We
2272.89. Source: Parametric survival analyses
from ASPECCT (A Study of Panitumumab Effi
With KRAS Wild-Type Metastatic Colorectal C
1380inputs and costs considered by the models (ie, KRAS
mutation testing, physician visits, diagnostic tests,
BSC, end-of-life care) are presented in Table III. All
costs were inﬂated to 2014 US dollars by using the
medical component of the Consumer Price Index.24
Utility Weights
Utility weights, used only in the cost-effectiveness
model, were based on EuroQol-5 Dimension ques-
tionnaire responses of patients with wild-type KRAS
(exon 2) mCRC from the ASPECCT clinical trial
during the progression-free period (average of screen-
ing and treatment visits during the progression-free
period) and during the disease progression period
(safety follow-up visit responses). Utility weights
were estimated from the questionnaire responses by
using the algorithm of Shaw et al25 for US patients
(Table III).
Outcomes Modeled
The model outcomes calculated for each treatment
regimen in the cost-minimization analysis included the
cost per treated patient, the cost per 100 treatedaplan-Meier
xponential
eibull
og-logistic
Cetuximab Kaplan-Meier
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Cetuximab Weibull
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d curves. Akaike information criterion for goodness-
ibull, 2384.95; exponential, 2261.54; log-logistic,
were performed on the February 5, 2013, data cut
cacy and Safety Compared to Cetuximab in Patients
ancer).
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Figure 4. Overall survival Kaplan-Meier and fitted curves. Akaike information criterion for goodness-of-fit of
overall survival curves: Weibull, 2585.46; exponential, 2506.62; log-logistic, 2515.79. Source:
Parametric survival analyses were performed on the February 5, 2013, data cut from ASPECCT
(A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS
Wild-Type Metastatic Colorectal Cancer).
C.N. Graham et al.patients, the cost savings per treated patient, and the
cost savings per 100 treated patients receiving pan-
itumumab monotherapy relative to cetuximab mono-
therapy.
The model outcomes calculated for each treatment
regimen in the cost-effectiveness analysis included
patient survival life-years, quality-adjusted life-years
(QALYs), and costs for health care resources. The
incremental costs and total life-years and QALYs were
calculated to obtain an incremental cost per life-year
gained and per QALY gained. All costs and outcomes
(beneﬁts) in the model were discounted by using the
suggested discount rate in the United States of 3.0%
per annum.26
In the cost-effectiveness analysis, the robustness of
the model methods, assumptions, and speciﬁc param-
eters were tested by examining the effect of using
alternative methods and data sources for the model
inputs in a series of focused scenario analyses con-
ducted around the assumptions and methods used to
calculate drug acquisition costs and subsequent treat-
ment. We also examined the effect of changing
parameters individually as part of 1-way sensitivityJune 2016analyses. In addition to 1-way sensitivity analyses, a
probabilistic sensitivity analysis was performed to
examine the effects of joint uncertainty across all the
parameters of the model.RESULTS
Deterministic Results
The results of the cost-minimization analysis
(Table IV) revealed lower projected drug acquisition,
administration, and adverse event costs for patients with
wild-type KRAS (exon 2) mCRC who received panitu-
mumab versus cetuximab. The projected total cost
savings was $9468 (16.5%) per patient treated with
panitumumab.
Results from the cost-effectiveness model (Table V)
demonstrated slightly better outcomes for patients
with wild-type KRAS (exon 2) mCRC who received
panitumumab versus cetuximab. The model projected
1.072 life-years for panitumumab and 1.051 life-years
for cetuximab. Adjusting for quality of life, panitu-
mumab was estimated to produce 0.736 QALY,
whereas cetuximab was estimated to produce 0.7261381
Table I. Regimen-specific input parameters: cost-minimization and cost-effectiveness models.
Input Parameter Panitumumab Cetuximab Source
Biologic therapy
Drug acquisition cost
ASP $91.23 $52.52 Payment allowance limits for Medicare Part B drugs22
(per 10-mg dose)
WAC $926.50 $514.55 Red Book23 (per 100-mg vial)
Chemotherapy IV
infusion 2-week
administration cost
$133.26 LD: $294.46 MD:
$266.52
Panitumumab is administered over 60 minutes27,28
Cetuximab loading dose is administered over 120 minutes and
maintenance doses over 60 minutes28,29
Average dose delivered 5.98 mg/kg LD: 394.10 mg/m2
MD: 247.52
mg/m2
ASPECCT Clinical Study Report Table 14-05.002.001 for
panitumumab and ASPECCT Ad Hoc Analysis Table
us-2.5.800.001 for cetuximab
Percentage of doses
administered
92.9 94.1 Ratio of actual to planned doses from ASPECCT Clinical Study
Report Table 14-05.002.002
Premedication
Drug acquisition cost
ASP $0.68 $0.68 HCPCS code J1200 for 50-mg dose of diphenhydramine22
WAC $0.82 $0.82 WAC per 50-mg dose of diphenhydramine, NDC 00641-0376-2123
Administration cost $30.09 $30.09 Centers for Medicare & Medicaid Services28
Percentage of doses
requiring
premedication
Minimum premedication for cetuximab is an H1 antagonist (eg, 50 mg
of diphenhydramine) IV 30–60 minutes before the ﬁrst dose
(ASPECCT protocol and Eli Lilly29); premedication for
panitumumab is not required (ASPECCT protocol)
First dose 0 100.0 Assumed no panitumumab-treated patients and all cetuximab-treated
patients were given premedication for ﬁrst infusion
Maintenance doses 2.8 12.5 Assumed percentage of patients observed to have an infusion reaction
(any grade) in ASPECCT would require premedication
maintenance doses
Subsequent-line therapy use (CE model only)
5-Fluorouracil 25.9% 28.2% ASPECCT Clinical Study Report Table 14-04.001.008.001
Irinotecan 12.6% 14.2%
Oxaliplatin 11.4% 12.2%
Cetuximab 7.8% 8.2%
Panitumumab 1.0% 2.4%
Bevacizumab 6.0% 6.4%
Leucovorin 6.2% 5.0%
Any antitumor
therapy for mCRC*
41.1% 42.2%
Percentage of doses
administered
93.5 Assumed average ratio of actual to planned doses for third-line
panitumumab and cetuximab (ASPECCT Clinical Study Report
Table 14-05.002.002)
Treatment duration 10 wk Assumed one half the duration of third-line treatment
Subsequent-line therapy drug acquisition cost
5-Fluorouracil
ASP $2.123 Payment allowance limits for Medicare Part B drugs22 (per 500-mg dose)
WAC $2.75 Red Book23 (per 500-mg vial)
Irinotecan
ASP $4.539 Payment allowance limits for Medicare Part B drugs22 (per 20-mg dose)
WAC $12.34 Red Book23 (per 40-mg vial)
Oxaliplatin
ASP $0.269 Payment allowance limits for Medicare Part B drugs22 (per 0.5-mg dose)
WAC $86.63 Red Book23 (per 50-mg vial)
Cetuximab
ASP $52.520 Payment allowance limits for Medicare Part B drugs22 (per 10-mg dose)
WAC $514.55 Red Book23 (per 100-mg vial)
Panitumumab
ASP $91.231 Payment allowance limits for Medicare Part B drugs22 (per 10-mg dose)
WAC $926.50 Red Book23 (per 100-mg vial)
Bevacizumab
ASP $65.664 Payment allowance limits for Medicare Part B drugs22 (per 10-mg dose)
WAC $649.14 Red Book23 (per 100-mg vial)
(continued)
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Table I. (continued).
Input Parameter Panitumumab Cetuximab Source
Leucovorin
ASP $4.308 Payment allowance limits for Medicare Part B drugs22
(per 50-mg dose)
WAC $4.40 Red Book23 (per 50-mg vial)
ASP ¼ average sales price; ASPECCT ¼ A Study of Panitumumab Efﬁcacy and Safety Compared to Cetuximab in Patients
With KRAS Wild-Type Metastatic Colorectal Cancer; CE ¼ cost-effectiveness; HCPCS ¼ Healthcare Common Procedure
Coding System; IV ¼ intravenous; LD ¼ loading dose; mCRC ¼ metastatic colorectal cancer; MD ¼ maintenance dose;
NDC ¼ National Drug Code; WAC ¼ wholesale acquisition cost.
*Any antitumor activity is less than the sum of the individual drugs because some patients received combination therapy.
Table II. Serious adverse event input parameters: cost-minimization and cost-effectiveness models.
Serious Adverse Event
Incidence, %
Hospital
Cost, $ SourcePanitumumab Cetuximab
Hypomagnesemia
(CE model only)
7.3 2.6 6939 Incidence: ASPECCT Clinical Study Report
Table 12-8: Overall Subject Incidence of
Adverse Events of Interest (Safety Analysis
Set)
Cost: Costs extracted from Burudpakdee
et al30 for all adverse events except
cardiac arrhythmia and infusion reactions
Cardiac arrhythmia costs estimated from
ICD-9 427.31 (atrial ﬁbrillation) from
HCUPNet31
Costs for infusion reaction extracted from
Foley et al32 and calculated as the
incremental cost of having a reaction
versus not having a reaction (ie, total
costs for those with a reaction minus
total costs for those without a reaction)
Assumed outpatient setting for grades 1
and 2 infusion reactions and emergency
department visit or inpatient
hospitalization for grades 3 and 4
infusion reactions
Infusion reactions, grades 1
and 2
2.6 10.7 3387
Infusion reactions, grades 3
and 4
0.2 1.8 14,454
Hypokalemia (CE model
only)
3.2 1.8 6401
Hypocalcemia (CE model
only)
1.2 1.2 6401
Acute renal failure
(CE model only)
0.8 1.2 12,013
Embolic and thrombotic
events, unspeciﬁed
(CE model only)
1.0 0.6 9832
Venous thromboembolism
(CE model only)
1.2 0.8 9832
Cardiac arrhythmia
(CE model only)
0.2 0.2 9021
Ischemic heart disease
(CE model only)
0.2 0.2 22,867
Arterial thromboembolic
events (CE model only)
0.2 0.0 22,867
ASPECCT ¼ A Study of Panitumumab Efﬁcacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type
Metastatic Colorectal Cancer; CE ¼ cost-effectiveness; HCUPNet ¼ Healthcare Cost and Utilization Project’s online query
system; ICD-9 ¼ International Classiﬁcation of Diseases, Ninth Revision.
C.N. Graham et al.
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Table III. Other input parameters: cost-minimization and cost-effectiveness models.
Input Parameter Value Source
Other medical costs
KRAS test $197.48 Final CMS 2014 KRAS genetic test national limit amount
(CPT code 81275)28
General practitioner ofﬁce visit
cost* (CE model only)
$107.83 Level 4 visit for an established patient (CPT code 99214)28;
assumed to occur every 4 weeks
Oncology specialist ofﬁce visit
cost* (CE model only)
$144.37 Level 5 visit for an established patient (CPT code 99215)28;
assumed to occur every 2 weeks
Computed tomography scan
cost (CE model only)
$327.42 Computed tomography scan with contrast of the abdomen
and pelvis (CPT code 74177)28; assumed disease
progression was monitored every 8 weeks, similar to
ASPECCT clinical trial protocol
BSC and end-of-life cost
(CE model only)
BSC costs per cycle $4493 End-of-life costs from Chastek et al33 for months 2–5 before
death were used to estimate costs for BSC treatment
End-of-life cost $24,563 End-of-life costs from Chastek et al33 for the last month
before death were used to estimate end-of-life/transition-
to-death costs
Utility weights (CE model only)
Progression free Utility weights estimated from analysis of EQ-5D responses
from ASPECCT during the progression-free period (average
of screening and treatment visits during the progression-
free period) by using the algorithm of Shaw et al25 for US
patients
Pooled 0.803
By treatment
Panitumumab 0.7962
Cetuximab 0.8096
Progressive disease Utility weights estimated from analysis of EQ-5D responses
from ASPECCT during the disease progression period
(safety follow-up visit responses) by using the algorithm of
Shaw et al25 for US patients
Subsequent antitumor
therapy
0.749
BSC 0.602
ASPECCT ¼ A Study of Panitumumab Efﬁcacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type
Metastatic Colorectal Cancer; BSC ¼ best supportive care; CE ¼ cost-effectiveness; CMS ¼ Centers for Medicare & Medicaid
Services; CPT ¼ Current Procedural Terminology; EQ-5D ¼ EuroQol 5-Dimension questionnaire.
*Scheduled physician visits did not include visits for grade 3/4 toxicity treatment or management that occurred on days other than
the day of treatment administration. Also, costs of scheduled physician visits during BSC after disease progression were captured as
part of the BSC costs and were not included in these cost estimates because the frequency of ofﬁce visits was likely to be different.
Clinical TherapeuticsQALY. BSC costs contributed the greatest proportion
of total costs modeled (46.0% for panitumumab;
43.5% for cetuximab), followed by monoclonal anti-
body drug acquisition costs (33.4% for panitumumab;
35.9% for cetuximab). Total drug costs for panitu-
mumab were lower than total drug costs for cetux-
imab ($50,360 vs $56,377). Costs for administration,
adverse events, and end-of-life care were also slightly1384lower for panitumumab than for cetuximab. How-
ever, costs for physician visits, monitoring for disease
progression, and BSC were slightly higher for panitu-
mumab than for cetuximab due to longer projected
survival. The incremental cost per life-year gained and
the incremental cost per QALY gained indicate that
with both end points, panitumumab dominated cetux-
imab (ie, panitumumab was less costly and hadVolume 38 Number 6
Table IV. Deterministic results: cost-minimization analysis.
Cost
Per 1 Treated Patient, $ Per 100 Treated Patients, $
Panitumumab Cetuximab
Savings per 1
Treated Patient Panitumumab Cetuximab
Savings per 100
Treated Patients
KRAS test 197 197 — 19,748 19,748 —
Drug acquisition 46,179 53,609 7430 4,617,853 5,360,863 743,010
Anti-EGFR 46,178 53 606 7428 4,617,836 5,360,625 742,789
Premedication 0.18 2.38 2.20 18 238.40 220.45
Administration 1382 2916 1534 138,209 291,599 153,391
Outpatient 1382 2916 1534 138,209 291,599 153,391
Hospitalization — — — — — —
Adverse events 118 622 504 11,790 62,220 50,430
Infusion
reactions
Grades 1 and 2 89 364 275 8876 36,358 27,481
Grades 3 and 4 29 259 229 2914 25,862 22,948
Total 47,876 57,344 9468 4,787,601 5,734,431 946,830
EGFR ¼ epidermal growth factor receptor.
C.N. Graham et al.slightly better outcomes than cetuximab). The results
from the cost-effectiveness analysis are consistent with
the ASPECCT primary analysis (HR, 0.97) showing
noninferiority of panitumumab relative to cetuximab
and slightly favoring panitumumab.Sensitivity Analyses
The 1-way sensitivity analysis from the cost-
effectiveness model indicated that model outcomes
were most sensitive to changes to the Weibull OS
treatment coefﬁcient, panitumumab drug costs, BSC
costs, and end-of-life costs. Scenario analyses con-
ducted around major model assumptions indicated
that the model was robust to alternative assumptions
of PFS and OS distributions, wastage, drug acquisition
costs, postprogression costs, and the progression-free
utility weight method used (Table VI).
The probabilistic sensitivity analysis from the cost-
effectiveness model was conducted by using the
observed uncertainty measures of the PFS, OS, and
other model inputs. Cost-effectiveness acceptability
curves were calculated from 10,000 iterations by using
the net monetary beneﬁt statistic across a range of
willingness-to-pay thresholds. The cost-effectivenessJune 2016scatter plot (Figure 5) and acceptability curves
(Figure 6) indicate that 92.5% of simulations were
below a willingness-to-pay threshold of $50,000 and
98.5% of simulations were below a willingness-to-pay
threshold of $100,000. In addition, 45.8% of simu-
lations revealed panitumumab to be less costly, with
minimally better outcomes, than cetuximab.DISCUSSION
Results Summary
Cetuximab or panitumumab monotherapy consti-
tutes a standard-of-care treatment in the management
of mCRC with wild-type RAS tumors.1–3 The
ASPECCT clinical trial met its primary end point,
reporting similar OS for both panitumumab and
cetuximab (HR, 0.97 [95% CI, 0.84–1.11]) in the
treatment of patients with chemorefractory wild-type
KRAS (exon 2) mCRC. The cost-minimization model
analysis conservatively used the panitumumab treat-
ment effect (PFS HR) of 1.0 from ASPECCT. Deter-
ministic results from the cost-minimization analysis
projected panitumumab to be cost-saving relative to
cetuximab ($47,876 vs $57,344) per patient. In a
separate model, a cost-effectiveness analysis was1385
Table V. Deterministic results: cost-effectiveness analysis.
Outcome/Cost Category Panitumumab Cetuximab
Difference Between
Panitumumab and Cetuximab
Outcome
Patient survival (undiscounted) 1.100 1.078 0.022
Life-years 1.072 1.051 0.021
Before progression 0.421 0.406 0.016
After progression 0.651 0.645 0.006
QALYs 0.736 0.726 0.010
Before progression 0.336 0.328 0.007
After progression 0.401 0.398 0.003
Cost category
KRAS test $197 $197 $0
Drug costs $50,360 $56,377 $6016
Before progression
Anti-EGFR $47,819 $53,453 $5634
Premedication $0.19 $1.45 $1.27
After progression $2541 $2922 $381
Administration $2101 $3635 $1535
Before progression $1431 $2905 $1474
After progression $669 $730 $61
Adverse events $1329 $1334 $5
Physician visits $2591 $2521 $70
Monitoring for disease progression $1070 $1041 $29
BSC $69,238 $68,321 $917
End-of-life $23,771 $23,786 $15
Total costs $150,657 $157,213 $6556
Incremental cost-effectiveness ratios of
panitumumab vs cetuximab
Incremental cost per life-year gained $307,432 (dominates*)
Incremental cost per QALY gained $648,345 (dominates*)
BSC ¼ best supportive care; EGFR ¼ epidermal growth factor receptor; QALY ¼ quality-adjusted life-year.
Note: Incremental cost-effectiveness ratios presented are calculated from model estimated cost, life-year, and QALY values
before rounding.
*Panitumumab is more effective and less costly than cetuximab. The outcomes results are consistent with the ASPECCT
(A Study of Panitumumab Efﬁcacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic
Colorectal Cancer) primary analysis (hazard ratio, 0.97), showing noninferiority of panitumumab versus cetuximab and
slightly favoring panitumumab (although this difference was not statistically signiﬁcant).
Clinical Therapeuticsconducted by using the actual treatment effect data
from the ASPECCT trial (cetuximab vs panitumumab:
PFS HR, 1.00 [95% CI, 0.88–1.14]; OS HR, 0.97
[95% CI, 0.84–1.11]) to compare the incremental cost
per QALY gained for panitumumab and cetuximab.
Results from the cost-effectiveness analysis projected1386panitumumab to be dominant relative to cetuximab,
with incrementally greater QALYs (0.736 vs 0.726)
and lower costs ($150,657 vs $157,213) per patient.
The outcomes estimated in this model were similar to
those of the ASPECCT primary analysis (HR, 0.97)
showing noninferiority of panitumumab versusVolume 38 Number 6
Table VI. Scenario analyses results: cost-effectiveness analysis.
Alternative Input
Parameter Scenario
Base-case
Parameter
Alternate Scenario
Parameter
Incremental Cost
per QALY Gained
ICER Change From
Base-case, %
Base-case analysis — — $648,345 Dominates* —
Wastage Wastage No wastage $646,640 Dominates* 0.3
Drug cost source ASP WAC $468,555 Dominates* 27.7
Cetuximab hospitalization
for ﬁrst administration
0% 100% $648,345 Dominates* 0
Best-ﬁt PFS curve Weibull Log-logistic $909,743 Dominates* 40.3
Weibull Exponential $715,855 Dominates* 10.4
Best-ﬁt OS curve Weibull Log-logistic $406,113 Dominates* 37.4
Weibull Exponential $379,303 Dominates* 41.5
Cetuximab oncologist
ofﬁce visit
Every 2 weeks Every week $557,573 Dominates* 14.0
Postprogression costs ASPECCT % All BSC $609,028 Dominates* 6.1
ASPECCT % All PD $ equal $670,409 Dominates* 3.4
Progression-free utility
weight method
Pooled By treatment $418,472 Dominates* 35.5
ASP ¼ average sales price; ASPECCT ¼ A Study of Panitumumab Efﬁcacy and Safety Compared to Cetuximab in Patients
With KRAS Wild-Type Metastatic Colorectal Cancer; BSC ¼ best supportive care; ICER ¼ incremental cost-effectiveness
ratio; OS ¼ overall survival; PD ¼ progressive disease; PFS ¼ progression-free survival; QALY ¼ quality-adjusted life-year;
WAC ¼ wholesale acquisition costs.
Note: ICERs presented are calculated from model-estimated cost, life-year, and QALY values before rounding.
*Panitumumab is more effective and less costly than cetuximab. The outcomes results are consistent with the ASPECCT
primary analysis (hazard ratio, 0.97), showing noninferiority of panitumumab versus cetuximab and slightly favoring
panitumumab (although this difference was not statistically signiﬁcant).
C.N. Graham et al.cetuximab, with a statistically nonsigniﬁcant OS trend
favoring panitumumab. Scenario analyses indicated
robust results, as modiﬁcations of key model assump-
tions consistently demonstrated panitumumab domi-
nance. Furthermore, when accounting for uncertainty
across all model parameters in the probabilistic
sensitivity analysis, panitumumab was cost-effective
at a willingness-to-pay threshold of $50,000 or more
in 492% of model simulations in the cost-
effectiveness analysis.
Limitations
The strength of our models reside in the use of data
from a well-conducted randomized Phase III head-to-
head clinical trial in a homogeneous patient popula-
tion. Considerable scrutiny was placed on toxicity
collection in this study, allowing for a more accurate
modeling of cost of toxicities amongst arms. However,June 2016as with any model, there were several limitations to
the analysis and modeling. Both models assumed dose
modiﬁcations and dose interruptions in clinical prac-
tice that mimic the ASPECCT clinical trial recommen-
dations. This scenario may not be necessarily true in
actual clinical practice. For example, many physicians
may carry through treatment with chronic aggressive
intravenous magnesium supplementation in a setting
in which no other treatment options may be available.
In addition, the management of skin toxicity in clinical
practice may vary from the ASPECCT clinical trial,
with variations in the rate of dose interruptions or
modiﬁcations and/or the implementation of dermatol-
ogy or podiatry consults. Furthermore, the intensity of
skin toxicity within a particular grade of toxicity can
vary from 1 patient to another and may not be
reﬂected adequately by the toxicity grading of the
National Cancer Institute and Common Terminology1387
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Figure 5. Probabilistic sensitivity analysis (PSA) cost-effectiveness scatter plot. *Quadrant 3 includes
iterations in which cetuximab is more effective and more costly than panitumumab. Thus, the
incremental cost-effectiveness ratio is switched and is interpreted as cetuximab compared with
panitumumab. Iterations greater than the willingness-to-pay (WTP) threshold indicate situations
in which panitumumab would be selected over cetuximab, given cetuximab is not cost-effective at
the specified WTP threshold. Q1 ¼ more costly, more effective; Q2 ¼ more costly, less effective;
Q3 ¼ less costly, less effective; Q4 ¼ less costly, more effective; QALY ¼ quality-adjusted life-year.
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Figure 6. Probabilistic sensitivity analysis cost-effectiveness acceptability curve. WTP ¼ willingness to pay.
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C.N. Graham et al.Criteria for Adverse Events. Despite these limita-
tions, the 1-way sensitivity analysis in the cost-
effectiveness model indicated relatively minimal impact
of panitumumab-related hypomagnesemia or grades 3
and 4 cetuximab infusion reactions on the cost-
effectiveness results.
In addition, all models are abstractions from real
clinical practice and do not take into account all costs
and attributes of patient care. However, we have
modeled costs that comprise the majority of total
costs and those that are likely different between the 2
treatments (eg, drug, administration, adverse events).
Several assumptions were taken into account in the
cost-modeling of an infusion reaction. Although most
of the clinical sites in the ASPECCT trial were outside
the United States, the rate of infusion reactions in the
ASPECCT patient population was assumed to be
similar for the US patient population. However, it is
well known that geographic variations exist in terms
of cetuximab infusion reactions.34–38 Therefore, the
cost-savings and cost-effectiveness of panitumumab
may vary across the United States, with likely higher
cost savings and better cost-effectiveness outcomes
with panitumumab than cetuximab in certain US
regions.CONCLUSIONS
These economic analyses comparing panitumumab and
cetuximab in patients with wild-type KRAS (exon 2)
mCRC suggest beneﬁts in favor of panitumumab,
with cost-savings of almost $9500 per patient in the
cost-minimization model, and an incremental cost per
QALY gained demonstrating panitumumab to be less
costly with marginally better outcomes than cetuxi-
mab in the cost-effectiveness model. Such cost-savings
can add up, considering that 440,000 new patients
are treated for mCRC every year, 40% to 50% of
whom are eligible for anti-EGFR therapy. In addition
to the potential economic advantage of panitumumab
in this setting, panitumumab offers the convenience of
biweekly administration over the weekly cetuximab
administration, signiﬁcantly reducing interruptions in
patient and caretaker schedules. Furthermore, panitu-
mumab has distinct advantages in terms of hyper-
sensitivity reactions, which can be life-threatening in
2% of patients receiving cetuximab but are rarely
seen with panitumumab. The advantages of panitu-
mumab in terms of hypersensitivity, scheduling, andJune 2016costs make it an attractive choice over cetuximab in
patients with chemotherapy-refractory CRC.
Because the model was based on a monotherapy
study in chemotherapy-resistant CRC, questions may
remain regarding its applicability to irinotecan þ anti-
EGFR therapy in refractory CRC. The majority of
patients in the United States receive cetuximab þ
irinotecan or panitumumab þ irinotecan in late-
treatment settings, rather than anti-EGFR monother-
apy. Although a direct comparison of the costs of
treatment with panitumumab and cetuximab has not
been performed in such settings, there is little evidence
to point to a discrepancy in interaction between these
2 monoclonal antibodies and variable chemotherapy
backbones. Therefore, we believe that these results
could be generalizable to anti-EGFR antibody þ
chemotherapy combinations; however, further analy-
sis (particularly in ﬁrst-line therapy) may be useful.ACKNOWLEDGMENTS
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